Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study
{{output}}
Background: Direct-acting antiviral (DAA) therapies have simplified HCV treatment, and publicly funded Canadian drug plans have eliminated disease-stage restrictions for reimbursement of DAA therapies. However other policies whic... ...
